These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15262296)

  • 1. Fibrates in the metabolic syndrome and in diabetes.
    Steiner G
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):545-55, vi-vii. PubMed ID: 15262296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
    Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
    Grundy SM
    Nat Rev Drug Discov; 2006 Apr; 5(4):295-309. PubMed ID: 16582875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis.
    Tkác I
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S2-9. PubMed ID: 15955370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
    Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
    J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2004 Dec; 3():10. PubMed ID: 15574199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
    Naruszewicz M
    Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination statin-fibrate therapy: safety aspects.
    Franssen R; Vergeer M; Stroes ES; Kastelein JJ
    Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 16. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortisol--cause and cure for metabolic syndrome?
    Walker BR
    Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes.
    Sanders BH; Lubsch LM; West DS
    Ann Pharmacother; 2006 Sep; 40(9):1517-21. PubMed ID: 16896016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.